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Abstract
Background: Standard of care primary treatment of carcinoma of locally advanced squamous cell head and neck
cancer (LAHNSCC) consists of platinum-based concomitant chemo-irradiation. Despite progress in the treatment of
LAHNSCC using modern radiotherapy techniques the outcome remains still poor. Using IMRT with SIB the escalation of
total dose to the GTV is possible with the aim to improve clinical outcome. This study tests the hypothesis if radiation
dose escalation to the GTV improves 2-year-LRC and -OS after concomitant chemo-irradiation.
Methods: The ESCALOX trial is a prospective randomized phase III study using cisplatin chemo-irradiation and the SIB-
IMRT concept in patients with LAHNSCC of the oral cavity, oropharynx or hypopharynx to escalate the total dose to the
GTV up to 80.5 Gy. Chemotherapy is planned either in the 1st and 5th week (cisplatin 20 mg/m2/d d 1–5 and d 29–33)
or weekly (cisplatin 40 mg/m2/d) during RT. RT is delivered as SIB with total doses of 80.5 Gy/70.0 Gy/56.0 Gy with 2.
3 Gy/2.0 Gy and 1.6 Gy in the experimental arm and in the control arm with 70.0 Gy/56.0 Gy with 2.0 Gy and 1.6 Gy. A
pre-study with dose escalation up to 77.0 Gy/70.0 Gy/56.0 Gy with 2.2 Gy/2.0 Gy and 1.6 Gy is demanded by the
German federal office of radiation protection (BfS). In the translational part of the trial 100 of the randomised patients
will be investigated by 18-F-FMiso-PET-CT for the presence and behaviour of tumor hypoxia twice in the week before
treatment start.
Discussion: The primary endpoint of the pre-study is acute radiation induced toxicity. Primary endpoint of the main
trial is 2-year-LRC. By using the dose escalation up to 80.5 Gy to the GTV of the primary tumor and lymph
nodes > 2 cm a LRC benefit of 15% at 2 years should be expected. The ESCALOX trial is supported by Deutsche
Forschungsgemeinschaft (DFG); Grant No.: MO-363/4-1.
Trial registration: ClinicalTrials.gov Identifier: NCT 01212354, EudraCT-No.: 2010-021139-15
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Background
Head and neck cancers are the seventh most frequent
cancer in Germany (estimated incidence of 50/100.000
per year, Deutsche Krebsgesellschaft). The German
Robert-Koch-Institut presented recently data on absolute
disease numbers of all tumor entities. In 2013 for head
and neck cancer there were 4.500 women and 13.000
men newly diagnosed in Germany [1]. For 2020 the new
diagnosis expectations are higher: women 5.500 and
men 14.300. Worldwide there are more than 550.000
new cases every year [2].
Head and neck cancers are representative for solid tu-
mours in which new biological-imaging-based treatment
strategies can be tested comparatively easily. This is true
especially with regard to the impact of tumour volume,
which correlates with cell number per tumour and
tumor hypoxia, on response after non-surgical treatment.
Concomitant chemo-irradiation is superior to radiation
alone in inoperable LAHNSCC. An absolute survival
benefit of 8% at 5 years favouring chemo-irradiation was
shown in the meta-analysis of the MACH-NC-group
(2000) [3]. The up-date of the MACH- NC-group in 2009
included studies between 1994 and 2000. Again there was
an absolute benefit of 6.5% for chemo-irradiation (inde-
pendent of the setting – postoperative or primary chemo-
irradiation) concerning the HR of death in comparison to
local treatment alone [4]. In 2011 the MACH-NC group
investigated the effect of chemo-irradiation in comparison
to radiotherapy and revealed a 5-year absolute benefit
(OS) due to concomitant chemotherapy for oral cavity:
8.9%, oropharynx: 8.1% and 4% for hypopharynx [5].
Besides tumor volume correlating with cell number
per tumor, hypoxia is a further important biological par-
ameter for tumor progression. Hypoxia increases radio-
resistance and is a predictive factor for local failure.
Hypoxia occurs in about 80% of head and neck tumors
(primaries and/or lymph nodes). Based on experimental
and clinical data, hypoxia is considered as a useful par-
ameter for pre-therapeutic stratification in future ran-
domized chemo-irradiation trials. More importantly,
hypoxic sub-volumes of tumors are also evolving as tar-
get volumes for radiotherapy (“dose painting”) in some
studies examining the significance of selective irradiation
dose escalation. To investigate the shift of the hypoxic
sub-volumes [18 F]-FMISO PET will be performed twice
within 1 week before start of radiation treatment.
Hypothesis of the trial
Over the last decade IMRT became a new standard in
radiotherapy. Different trials used the advantage of IMRT
concerning target volume coverage and protection of or-
gans at risk. Analyses of acute toxicity of IMRT revealed
advantage for lower toxicity compared to 3D-conformal
radiotherapy with comparable treatment results.
The 2-year local control rate varies between 77–98%
and the loco-regional control at 2 years between 86%–
100% for non-selected tumor stages [6–8]. Two studies
reported 2-year overall survival between 90–94% [9, 10]
for patients with locally advanced disease.
The ESCALOX trial investigates whether dose-
escalated SIB-IMRT to the primary tumor and involved
cervical lymph nodes (≥2 cm) with concurrent cisplatin
chemotherapy improves loco-regional control within
2 years by 15% in comparison to conventional SIB-
IMRT with concurrent cisplatin.
The experimental arm of the ESCALOX-trial has not
yet been tested in a multi-institutional setting. Taking
into account all the mentioned results on acute and late
toxicity it seems possible to apply dose escalated radio-
therapy with optimization of the IMRT-plan concerning
the organs at risk.
Methods/design
Trial organization/coordination
ESCALOX is a prospective randomized multicentre na-
tional phase III trial. The performance of the study is
supported by Deutsche Forschungsgemeinschaft (DFG;
MO- 363/4-1). ESCALOX is an investigator initiated
trial (IIT) and is coordinated by the Department of
RadioOncology and Radiotherapy of the Technical
University of Munich. The Münchner Studienzentrum
(MSZ) at the Technical University of Munich (Munich
trial coordinating centre) is responsible for overall trial
management, trial registration, database management,
quality assurance including monitoring and reporting.
The radio-oncological quality assurance (delineation and
treatment planning) is centrally performed by the de-
partments of radiation oncology of the two university
hospitals in Munich (Technical University of Munich
and Ludwigs-Maximilians-University Munich).
Ethics, informed consent and safety
The final protocol was approved by the ethics committee
of the Medical Faculty of the Technical University of
Munich (2847/10 Af) and the German Federal Institute
for Drugs and Medical Devices (Bundesinstitut für
Arzneimittel und Medizinprodukte - BfArM; BfArM-
registration number 4036421) and the German Federal
Office of Radiation Protection (Bundesamt für Strah-
lenschutz – BfS) (BfS-registration number Z5-22463/2-
2011-011).
Written informed consent is obtained from each pa-
tient in oral and written form before inclusion in the
trial. Nature, scope and possible consequences of which
will been explained by the responsible physician.
An independent safety board of four experts was
named (three of them are radio-oncologists, one statisti-
cian). After the end of the pre-study as recommended by
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the German Federal Office of Radiation Protection a
safety report will be sent to the BfS. During this
phase there will be a stop of 6 months of the trial
until the BfS gives permission for further recruitment
of patients.
Study design
The ESCALOX trial is an investigator initiated (IIT),
rater-blinded, multicentre national phase III trial com-
bining dose escalated radiotherapy of macroscopic
tumor in LAHNSCC with the standard cisplatin chemo-
therapy (Fig. 1). The German Federal Office of Radiation
Protection (BfS) demanded the enforcement of a pre-
study to check the safety of a dose-escalation trial con-
cerning the acute toxicities in a first step up to 77.0 Gy
for twenty patients.
IMRT or VMAT will be performed to apply the RT as
simultaneous integrated boost. The ESCALOX trial en-
rols patients with LAHNSCC of the oral cavity, orophar-
ynx or hypopharynx. Patients will be treated by the
University Departments of Radiation Oncology and
Radiation Therapy in Germany.
The primary endpoint of the pre-study as recom-
mended by the German Federal Office of Radiation
Protection (BfS) will be the assessment of acute toxicity.
The primary endpoint of the main study is the local-
regional control (LRC) at 2 years.
The secondary endpoints are disease-free survival
(DFS), progression-free survival (PFS), overall survival
(OS), acute and late radiation effects, adverse events,
tumor hypoxia status investigated by 18-F-FMiso-PET.
Patient selection
As defined by the German federal office of radiation
protection a pre-study is performed in a step wise de-
sign. In the pre-study 20 patients will be included. The
inclusion criteria are the same. For the main study a
total of 250 subjects with LANHSCC are planned to re-
cruit. For inclusion and exclusion criteria see Table 1.
Pathology
From the specimen taken during pan-endoscopy the
tumor histology and HPV16 status will be determined.
Imaging
During screening the standard staging program to ex-
clude lung and liver metastasis or secondary cancer is
performed by CT Thorax and ultrasound of the liver.
CT or MRI of the head and neck is performed at the
time of screening and then at every follow-up visit using
the RECIST-criteria version 1.1.
Safety
Safety pre-study
The federal office of radiation protection (BfS) requires
the successful completion of a pre-study before the main
study is allowed to recruit patients.
The pre-study is planned to be carried out as follows:
A pre-study was initiated before starting treatment ac-
cording to ESCALOX’s planned study arms (arm A: the
experimental group receiving a dose escalation up to
80.5 Gy and arm B: the control group receiving a stand-
ard dose up to 70.0 Gy).
Fig. 1 ESCALOX - Trial scheme
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The pre-study is analogue to the experimental group
A but the dose-escalation to the macroscopic tumor and
involved lymph nodes ≥ 2 cm is restricted to 2.2 Gy up
to a total dose of 77.0 Gy in this SIB-volume.
In the first step 6 patients will be treated up to 77.0 Gy.
After the last patient finished the RT-course there was an
interval of 6 weeks defined to assess acute toxicity. When
the last patient has finished the 6 weeks of follow-up and
no more than 1 of the 6 patients reached grade 4 radiation
induced toxicity (CTCAE v. 4.0), further 14 patients will
be allowed to enter the pre-study. For all of these 20 pa-
tients the 6 weeks follow-up is fixed to assess acute tox-
icity as mentioned above. If no more than 2 out of all 20
patients reached grade 4 toxicity (CTCAE v. 4.0) at this
time (6 weeks after end of treatment) recruitment for the
main part of the ESCALOX trial with randomization into
arms A and B is allowed to begin.
Safety main study
Randomization of patients into the main part of the
ESCALOX trial is only possible after successful comple-
tion of the pre-study.
For the main part of the trial there are the same condi-
tions determined by the German federal office of radiation
protection (BfS) for a step wise recruitment of patients to
the experimental arm as for the pre-study. Six patients per
study arm will be allowed to be treated (arm A in the
SIB80.5Gy-volume up to 80.5 Gy and in arm B in the
SIB70Gy-volume up to 70 Gy). “Early” follow-up for these
patients is defined with 6 weeks after the end of therapy. If
the last patient has finished the 6 weeks of follow-up and
no more than 1 of the 6 patients in arm A (dose escalation
up to 80.5 Gy) reached grade 4 radiogenic toxicity (CTCAE
v. 4.0), then further 14 patients per arm will be allowed to
be treated. Patient “early” follow-up will continue for at
least 6 months after radiation treatment has ended.
After the end of this 6 months period all toxicities
have to be reported to the BfS. Only with a new permis-
sion of the BfS further patients can be recruited and
treated in the ESCALOX trial.
Adverse event (AE)
Radiotherapy-related toxicities will be assessed using the
NCI Common Toxicity Criteria (CTCAE v.4.0).
Serious Adverse Events (SAE)
In this trial the following are not to be classified as
Serious Adverse Events:
– Admission to hospital required by the protocol
– Admission to hospital for management of the
underlying disease
Table 1 Inclusion and Exclusion criteria of the ESCALOX-trial; (*) A tumour is classified as non-resectable if the probability of a
complete tumor resection is estimated at a very low level (non-R0). The decision to classify a tumor as non-resectable has to be
confirmed by consent of ENT-specialist, oral surgeon, radio-oncologist, radiologist and pathologist. Detailed criteria of irresectability
see Adelstein et al. [55]
Inclusion criteria Exclusion criteria
▪ Signed written informed consent
▪ Age≥ 18 ≤ 70 years
▪ Independent of gender
▪ Independent of race
▪ ECOG 0 – 2
▪ Tumor of oral cavity, oropharynx or hypopharynx
▪ Histology: squamous cell carcinoma, HPV-negative
▪ Curative treatment intended
▪ Tumor is classified as irresectable [11]*
▪ Woman of child-bearing age: negative pregnancy test in serum
▪ Contraception in male and female patients and their partners if of
childbearing potential, willingness to use effective contraceptive
method for the study duration and 2 months post therapy
▪ Sufficient bone marrow reserves during 7 days before study
inclusion; (leukocytes ≥ 4 × 109/l, absolute no. of neutrophiles
(ANC)≥ 2 × 109/;
▪ thrombocyte count≥ 100 × 109/l; hemoglobin≥ 10 g/dl)
▪ adaequate liver function during 7 days before study inclusion
(total bilirubine ≤ 2,5 × ULN (upper limit of normal),
ASAT/ALAT ≤ 2,5 × ULN,
▪ alkaline phosphatase ≤ 2,5 × ULN of the institution’s normal value)
▪ adequate kidney function during 7 days before study inclusion;
serum creatinine≤ 130 μmol/l; creatinine clearance≥ 70 ml/min
▪ all patients should have a dental examination before starting
therapy and if necessary be treated, adaptation of a teeth
protection bar
▪ a percutane feeding tube should be applied before start of
treatment
▪ Infiltration of the mandible and/or larynx
▪ HPV-positive proven tumors
▪ impaired renal and/or liver function
▪ secondary malignancy, unknown primary cancer, nasopharynx
cancer or
▪ salivary gland cancers
▪ Metastatic disease
▪ Another cancer within 5 years of study entry
▪ Serious concomitant disease or medical condition
▪ Pregnancy or lactation
▪ Women of child-bearing potential with unclear contraception
(postmenopausal
▪ women must have been amenorrheal for at least 12 months to be
considered of non-childbearing potential)
▪ previous treatment with chemotherapy, radiotherapy or surgery in
head and neck (except an excisional biopsy or biopsy for histology
and surgery for benign disease)
▪ concurrent treatment with other experimental drugs or participation
in another clinical trial with any investigational drug within 30 days
prior to study screening
▪ life expectancy of < 1 year
▪ contraindications to receive Cisplatin
▪ social situations that limit compliance with study requirements
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– Disease progression. However if, due to disease
progression, a death occurs during the reporting
period, it should be reported as SAE.
– Myelo-suppression, impaired renal function after
cisplatin chemotherapy, acute side effects of
radio-chemotherapy (such as fever, infection,
bleeding and related hospitalizations, mucositis,
radiodermatitis, dysphagia, odynophagia).
These events are expected events in the treatment of
malignancies of the head and neck region. They should




Before the initiation of a trial centre each site has to per-
form a “dummy run” to demonstrate that the centre
complies with the specific study requirements for delin-
eation, IMRT planning, dose distribution and treatment
delivery. For the dummy run a planning CT will be sent
by the IMRT-planning QA centre to each participating
institution and the results (structures, isodoses, DVH’s)
are evaluated by the QA centre. When the dummy run
is successfully completed, a site will be allowed to recruit
patients for the study. The first 3 patients of a trial site
will be checked for centrally QA.
Study treatment
Chemotherapy
The chemotherapy of the ESCALOX trial will contain a
platinum based protocol. The application of Cisplatin
20 mg/m2/d in week 1 (d1-5) and 5 (d29-33) as well as
Cisplatin given in a weekly schedule with 40 mg/m2/d q
d7 (max. 6 cycles) is allowed. In the case of impairment
of renal function due to cisplatin the switch to carbopla-
tin with AUC 2 in a weekly application scheme is
allowed.
Radiation therapy
The use of linear accelerator or a tomotherapy machine
with nominal photon energy ≥ 6 MV is allowed. Electron
beams are prohibited. The recommended photon energy
is 6 or/and 10 MV. Only IMRT with SIB-technique is
allowed. All fields of the IMRT-plan will be treated on
every treatment day. It is recommended to avoid beams
through sensitive structures (OARs) i.e. the eyes. The
radiotherapy course has to be completed with 35 frac-
tions in 55 days (with holidays, weekends, planned inter-
ruptions: day off, machine maintenance).
Re-treatment planning
In all cases a second and a third planning CT should
be done after 15 and 25 fractions of radiotherapy.
Re-Planning has to be done if changes of the GTVPT+LN
are clinically significant. If there is > 5% loss of body
weight and/or > 1 cm difference in any set-up parameter
during treatment a re-planning CT should be performed
and the treatment plan has to be adapted. The use of
image guidance is recommended.
Planning priorities
a) The planning target volumes (SIB 56, SIB 70 and
(SIB 77) SIB 80.5) should be delineated in the way
that there is a sufficient level of homogeneous tissue
for adequate dose homogeneity within the PTVs.
b) For the OAR constraints the biological equivalence
dose for 2 Gy (EQD2) using the α/β – value of 3 is
calculated.
The PTV prescription dose followed by the OAR-
constraints (see Table 2) has the highest priority.
a) Dose prescription of SIB 80.5, SIB 70, SIB 56.
b) OAR (spinal cord, brainstem, Glottis, mandible; in
this order).
c) Further aim of the planning: total dose to the saliv-
ary glands as low as possible.
Target volumes and dose prescription
Target volume definitions and delineation for control and
experimental group (main study)
Gross tumor volume (GTV): The description of the
gross tumor volume is based on CT and optionally MRI
scan, endoscopic and clinical examinations as well as
additional imaging.
A lymph node should be classified as involved, if it
has/there are
 diameter ≥ 1 cm (jugulo-digastric lymph nodes
>1.1–1.5 cm) in the first echelon of the tumor
 diameter ≤ 1 cm with spherical shape in the first
echelon of the tumor





(PRV: Myelon + 5 mm)
Mandatory Dmax < 50 Gy2 or
No more than 1 cm3 > 45 Gy2
Brachial plexus Mandatory 60 Gy2
Brainstem Mandatory Dmax < 54 Gy2 or no more than
1 cm3 > 54 Gy2
Optical nerve Mandatory Dmax < 54 Gy2
Mandible Recommended Dmax < 70 Gy2 or no more than
1 cm3 > 70 Gy2
Glottis (outside PTV) Recommended 2/3 < 50 Gy2; Dmean < 45Gy2
Gl. parotis Recommended Dmean < 26 Gy2; D50 < 30 Gy2
20 cm3 of both < 20 Gy2
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 lymph nodes containing necrotic areas
 multiple (minimal 3) lymph nodes of the ipsilateral
neck of the primary tumor.
All these lymph nodes should be delineated for GTV.
Clinical target volume (CTV) is defined as the GTV
plus regions classified to be at risk for microscopic
spread. The extension of this volume is determined by
the radio-oncologist.
CTV 70 is defined as GTV of the primary tumor plus
1 cm and GTV of the involved lymph nodes plus 0.5 cm
but for cranio-caudal direction also 1 cm (for control
group and for experimental group).
CTV 56 is defined as elective lymph node levels (for
control group and for experimental group).
Planning target volume (PTV) here deemed as SIB
56 and SIB 70 for experimental and control group.
SIB 56 is defined as an additional set-up margin
around CTV 56 in all directions to compensate for mor-
phological changes (i.e. weight loss), set-up deviation
and internal organ motion.
0.5 cm as safety margin is recommended for the
upper cervical structures and 0.7 cm for the lower
cervical structures. Exceptions are the direct neigh-
borhood of critical organs as the spinal cord or other
organs at risk.
A skin sparing of 0.3 cm is recommended unless the
tumor invades near the skin or e.g. into the sternocleido-
mastoid muscle.
In addition, the set-up margin should be defined ac-
cording to the results on set-up error for IMRT at each
participating center.
The SIB 70 will be derived from the CTV 70
(automatically contoured margins by the planning
system) as described above. The SIB 70 has to be
adapted by hand at each planning CT slice to organs at
risk and anatomical boundaries.
Pre-Study: Special Definition of dose escalated planning
target volume (SIB 77.0) for the pre-study group in
step-wise recruitment
Dose escalated volume (deemed as SIB 77.0): The
dose escalated volume is defined as the gross tumor vol-
ume (GTV) of the primary tumor (PT) and all involved
lymph nodes (LN) with a minimal axial diameter > 2 cm.
At critical structures (e.g. mucosal sites, vessels, skin)
the GTV is reduced by 0.3 cm (inner margin). Treat-
ment planning will be performed without set-up error
for the SIB 77.0.
All lymph nodes detected as involved with a minimal
axial diameter of 2 cm will be also included as SIB 77.0.
For definition of SIB 70 and SIB 56 see above
(Planning target volume (PTV) here deemed as SIB 56
and SIB 70).
Special Definition of dose escalated planning target
volume (SIB 80.5) for the experimental arm (group
A) Dose escalated volume (deemed as SIB 80.5): The
definition for the SIB 80.5 uses the same guideline as for
SIB 77 in the pre-study. Planning will be performed
without set-up error for SIB 80.5.
Description of delineation of SIB 70 and SIB 56 is
given above.
The dose constraints for organs at risk (OAR) are
shown in Table 2.
Evaluation of therapy outcome
CT or MRI of the head and neck is performed at the
time of screening and then at every follow-up visit
(4 month interval during the first two follow-up years)




Sample size calculations are based on the Log-rank test
for superiority of the experimental arm over the com-
parator arm in LRC-survival over two years. The two-
year LRC-survival is expected to be about 60% in the
comparator group and about 75% in the experimental
group. When the sample size in each group is 125, the
one sided Log-rank test will have power of about 80% to
detect the assumed difference at the 0.05 level. There-
fore, 250 patients need to be recruited in the trial, 125 in
each arm.
Due to missing alternative therapy concepts in non-
resectable LAHNSCC, the expected compliance rate will
be over 95%. Missing values will be conservatively
treated: In the control arm, missing values will be im-
puted by the longest observed loco-regional survival
time. In the experimental arm, missing values will be set
to the time of censoring.
Because of the pre-study requirements of the BfS the
pre-study will include 20 patients. These 20 patients are
on top of the calculated 250 patients for the whole trial.
Statistical methods
Primary efficacy endpoint analysis for the main part of the
trial
The primary efficacy endpoint of the trial, LRC-survival
over two years, will be tested for superiority of the ex-
perimental arm over the comparator arm using the one-
sided Log-rank test at the 0.05 significance level on the
ITT set. LRC-survival is defined as time to local relapse
or death calculated from start of radiotherapy.
The corresponding hypotheses are:
H0: Se(t) ≤ Sc(t) vs. Ha: Se(t) > Sc(t),
Se and Sc denote the two-year LRC-survival in the ex-
perimental arm and in the control arm respectively.
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Secondary efficacy and safety endpoint analyses
Secondary efficacy and safety endpoints will be analyzed
in an explorative manner on a 5% significance level.
Kaplan-Meier estimators and life-table methods will be
used for the analysis of time-to-event data and life-table
data. Cumulative incidence estimators will be used in
case of competing risk. The reproducibility of PET hyp-
oxic regions will be evaluated as the proportion of over-
lapping voxels. Continuous endpoints will be analyzed
with the t-test (Mann–Whitney-U test if not normal).
Categorical endpoints will be analyzed with the Chi-
squared test (Fisher’s exact test if the expected cell fre-
quency is less than 5). Repeated measures will be ana-
lyzed by paired-samples t-test, Wilcoxon singed-rank
test or mixed models.
Missing data
Missing values will be conservatively imputed for the as-
sessment of the primary endpoint: In the control arm,
missing values will be imputed by the longest observed
loco-regional survival time. In the experimental arm,
missing values will be set to the time of censoring. The
primary endpoint will also be analyzed as a secondary
endpoint without imputation. Imputation is not per-
formed for the secondary endpoints.
Interim analysis plan
On behalf of the BfS-requirements interim safety ana-
lysis as described above are necessary. For the safety in-
terim analysis after the first 60 patients neither the
primary nor the secondary endpoints will be assessed.
Primary endpoint will be assessed after two year
follow-up of the last included patient.
Discussion
The addition of concomitant chemotherapy to radiother-
apy, irrespective of fractionation schedule, increases
overall survival by 12 months [11]. In the 2011 meta-
analysis of the MACH-NC-group the additional effect of
chemotherapy concerning HR of death was calculated to
be 0.88 [5]. 5-FU and cisplatin or cisplatin mono based
concomitant chemo-irradiation gained the best survival
benefit compared with other cytostatic drugs [4].
The chemotherapy treatment of the ESCALOX trial
will use cisplatin weekly with 40 mg/m2/day or cisplatin
in the 1st and 5th week of the radiotherapy given on
5 days with a cumulative dose of 200 mg/m2 in both
schedules. At this time there is still controversial debate
on the best cisplatin regimen weekly vs. three weekly
[12] and on the number of cycles [13].
In spite of the significant clinical benefit from con-
comitant radio-chemotherapy, there is still the need for
further improvement. Two and 5 year loco-regional con-
trol rates after combined therapy are given from 40% to
65%. These disappointing numbers indicate that most
loco-regional recurrences are observed within the first
2 years after treatment and that overall survival consid-
erably declines with further follow up [14]. The latter is
also the result of a high likelihood of non-cancer deaths
related to the smoking and drinking habits of many head
and neck cancer patients [15]. The overall survival in the
same trials at 2 and 5 years ranges between 50% to 65%
and 35% to 45, respectively. The absolute gain of 5-y-OS
is 6.5–8% due to concomitant chemotherapy [4, 5].
In clinical trials testing chemotherapy in combination
with identical radiotherapy regimens in all arms of the
study, loco-regional control does not correlate well with
overall survival. In contrast, in randomized trials ad-
dressing radiation dose or fractionation schedules loco-
regional control has been shown to be a reliable surro-
gate marker of overall survival [14]. Any improvements
in overall survival by dose escalation of radiotherapy
with constant overall treatment time has to be attributed
to an increase in clonogenic tumor cell kill within re-
gions receiving an escalated dose, and in this way caused
by better loco-regional control.
Data on long term outcome of different fractionation
schedules are now available. The long term results of the
RTOG 90–03 trial presented the hyper-fractionation
arm with twice daily 1.2 Gy up to 81.6 Gy having the
best results concerning 5 y OS (HR = 0.81) and 5 y LRC
(HR = 0.79) [16]. This trial compared 4 fractionation
schedules without chemotherapy: hyper-fractionation
(HF) with 1.2 Gy twice daily up to 81.6 Gy; normo-
fractionation (NF) of 2 Gy up to 70 Gy; accelerated
radiotherapy (AF) with split (1.6 Gy twice daily up to
38.4 Gy – two weeks break – 1.6 Gy bid up to 67.2 Gy)
and the concomitant boost schedule (AF + ccb) with
1.5 Gy and 1.8 Gy up to 72 Gy. At 2 years HF and AF +
ccb yielded best loco-regional control. In comparison to
NF all patients treated by altered fractionation schedules
developed more acute side effects [17]. The long-term
follow-up data of RTOG 90–03 showed superiority of
the HF scheme (81.6 Gy) concerning 5y-OS HR =0.81
and 5y-LRC HR = 0.79; p = .05). Acceleration appeared
to increase the 5y toxicity [16].
Budach et al. [18, 19] compared in the German ARO
95–06 study two hyper-fractionated accelerated frac-
tionation schedules with chemotherapy (5-FU and
Mitomycin C) 70.6 Gy and without chemotherapy but
a dose escalation up to 77.6 Gy concerning the loco-
regional control. The 5- and 10-year results favored
the concomitant chemo-irradiation arm with 49.9%/
38.0% vs. 37.4%/26.0% for loco-regional control and
also for overall survival with 28.6%/10% vs. 23.7%/9%.
In the 10 year analysis there was the remark that the
association between treatment arm and LRC was only
found for oropharyngeal cancer.
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Considering the results of the ARO 95–06 [18, 19] and
the RTOG 90–03 [16, 17] it is possible to apply a total
dose of 77.6 to 81.6 Gy hyper-fractionated (accelerated) to
the head and neck region concerning the normal tissue
tolerance. In the ARO 95–06 trial the dose escalation
alone could not outweigh the effect of omitting concomi-
tant chemotherapy. Both trials used 3D-conformal radio-
therapy. By radiobiological modelling was shown that the
combination of chemotherapy reaches an improvement of
LRC which is not possible by radiotherapy dose-escalation
alone [20, 21].
The acute toxicities of the ARO 95–06 trial were for the
radiotherapy arm (77.6 Gy) concerning mucositis III°/IV°
75.7% and for the radio-chemotherapy arm (70.6 Gy)
65.7%. Grade III and IV acute radiodermatitis occurred in
46.3% (radiotherapy alone) vs. 29.6% (radio-chemother-
apy) using photon and electron techniques. The amount
of toxicity should be decreased by using IMRT in the pre-
sented protocol as reported in many publications on
IMRT approach in head and neck cancer RT.
Fu et al. reported a grade III acute mucositis of 25%
for 70 Gy (normo-fractionated - NF), 41% for 81.2 Gy
(hyper-fractionated accelerated - HF) and 46% for 72 Gy
(accelerated fractionated with concomitant boost –
AF + ccb). A mucositis of grade IV developed in only
0–1% of all patients. The acute xerostomia grade II
rate was comparable between all groups (64–72%).
Over all patients of the RTOG trial 90–03 mainly a
grade II acute radiodermatitis developed (49–55%).
Seven percent of the normo-fractionated (NF) group
(70 Gy) and 11% of the hyper-fractionated (HF) respect-
ively the accelerated concomitant boost (AF + ccb) group
suffered from acute radiodermatitis of grade III [17].
From literature it is known that late toxicities of the
above mentioned therapy schemes are comparable. Over
the last decade there were 3 randomized trials per-
formed comparing IMRT with conventional radiother-
apy [22–24]. The primary endpoint of all trials was the
development and severity of xerostomia. In a random-
ized controlled setting the hypothesis of reducing xeros-
tomia by IMRT was verified. Focusing clinical outcome
(LRC and OS) all three trials revealed comparable re-
sults. But none of the trials were powered to detect dif-
ferences in clinical outcome data.
Data from published series on simultaneous integrated
boost technique for locally advanced head and neck can-
cer using single doses between 2.2 Gy – 2.4 Gy up to a
total dose range from 60–70 Gy showed tolerable acute
side effects. Guerrero Urbano et al. 2007 [25] and
Schwartz et al. 2007 [26] used single doses of 2.4 Gy up
to 60–67.2 Gy. Schwartz et al. reported on 49 patients of
whom 92% completed therapy without interruption.
The majority (59%) of the patients had concomitant
chemotherapy. The only grade IV acute toxicity was
related to dysphagia (acute mucositis I° 12%, II° 32%, III°
55%; acute dysphagia I° 40%, II° 14%, III° 24%; acute
xerostomia I° 36%, II° 12%, III° 3% and acute radiodermati-
tis I° 3%, II° 30%, III° 59%; weight loss in 22% of patients).
In one patient an osteoradionecrosis occurred. Guerrero
Urbano et al. [25] reported on 87% of stenosis or strictures
of the esophagus.
De Arruda et al. (2006) [27] reported on 72% grade III
and IV acute mucositis and 20% grade III and IV acute
radiodermatitis using 2.2 Gy per fraction up to 70 Gy
combined with concomitant cisplatin.
The acute mucositis III° and IV° is comparable be-
tween the series by de Arruda et al. (2006) [27] and the
ARO 95–06 trial by Budach et al. (2005) [18]. Most of
the SIB-trials using total doses about 70 Gy reported on
~ 50% acute mucositis III°.
Studer et al. (2006) [9] used three different SIB sched-
ules (2.0, 2.11 or 2.2 Gy per session) and concluded that
a SIB single dose of 2.2 Gy is not recommended for tu-
mors involving laryngeal structures (two IV° reactions
(dysphagia, laryngeal fibrosis)).
Most concern by using SIB-concepts with dose es-
calation is the development of late mucosal ulcer-
ation. In some cases described these ulceration arose
3 to 10 months after the end of radiotherapy [28–31].
The ulcerations were often located in the primary tumor
region. Interestingly, in some cases a spontaneous healing
was seen. Some of the patients who developed mucosal ul-
ceration had persistent alcohol and tobacco abuse after
the end of therapy. Because of these findings the German
Federal Institution of Radiation Protection recommended
to perform a pre-study to investigate the safety of the
planned dose escalation in two steps.
Distinct dose response curves for radiotherapy have
been calculated from clinical studies on head and neck
cancer [20]. According to this data, one would expect an
improvement of loco-regional control of an average 10%
(range 6.9–40%) by a dose escalation of 10%. However,
the available data are consistent with the hypothesis that
the slope of dose response in large tumors is consider-
ably shallower. The latter is likely related to the relatively
larger hypoxic areas in large tumors [32, 33].
Generally, in head and neck tumours hypoxia plays a
major role. In clinical radiation oncology it could be
proven that hypoxia is correlated with a worse prognosis
in especially in head and neck cancer [34–36].
Hypoxia reduces radiation- and chemo-sensitivity to a
considerable extent as shown also in many experimental
investigations. Using PET imaging and appropriate
markers, hypoxia is found in about 80% of patients with
advanced head and neck cancers [37, 38]. By using PET
tracers which selectively concentrate in hypoxic cells
(F-Miso) the visualization of hypoxic regions became
possible [37, 39–44].
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Retrospective data on head and neck cancer indicates
that loco-regional control is already excellent with stand-
ard radio-chemotherapy if tumors without any sign of
hypoxia on [18 F]-FMISO PET scans were treated. Lee
et al. [45] showed for head and neck tumors with hyp-
oxia detected by [18 F]-FMISO PET and treated using
IMRT excellent loco-regional control (3y-LRPFS of
95%). Loco-regional control in head and neck tumors
with significant enhancement in the [18 F]-FMISO PET
was poor in a study by Thorwarth et al. [46]. Zips et al.
showed a strong association for locally advanced head
and neck cancer patients with stage III and IV of
FMISO-image parameters and LPFS. The strongest asso-
ciation was seen for the PET investigations performed
during week 1 and 2 of radiotherapy [47]. The stability
of hypoxic tumor sub-volumes detected by FMISO-PET
was investigated by Bittner et al. in 16 patients with
LAHNSCC. They found in patients with hypoxic tumors
in comparison between FMISO-PET 1 and 2 (two weeks
apart) at the beginning of the radio-chemotherapy. In
patients with persistent hypoxia after 2 weeks of treat-
ment, the hypoxic sub-volumes showed relative geo-
graphical stable information [48].
According to this data, preferentially patients with sig-
nificant tumor hypoxia would benefit from dose escal-
ation. Since hypoxic sub-volumes are predominantly
observed more centrally in the tumor, dose escalation in
the central parts of the tumor, as done in the experimen-
tal arm of this study, should cover most hypoxic sub-
volumes.
We hypothesize that patients with tumours exhibiting
significant enhancement in the [18 F]-FMISO PET, will
have a larger benefit from dose escalation than patients
with no [18 F]-FMISO-enhancing tumours in terms of
loco-regional tumor control.
IMRT provides a better sparing of normal tissues.
In addition to better sparing of normal tissues, IMRT
also allows escalating the radiation dose selectively to
sub-volumes of the tumour. Simultaneously Integrated
Boost technique (SIB-IMRT) is well described and
evaluated especially regarding its acute and late tox-
icity [9, 30, 49–51]. This is true for salivary glands
and for the mucosa [22–24, 27, 52–54].
Nevertheless, dose escalation to large parts of the tumor
is inherently accompanied by the risk of more acute and
late toxicity [28–31]. In consideration of this risk, dose es-
calation was restricted to 80.5 Gy in the current study, al-
though theoretical considerations indicate that even
higher doses could be required in hypoxic areas. A few
other trials test dose escalation restricted to the [18 F]-
FMISO PET positive regions of the tumours (“Dose
Painting by Numbers”). In Denmark a phase I trial for
FDG based dose painting up to 82 Gy in 2.34 Gy was initi-
ated and first results were published [31].
Abbreviations
AF: Accelerated Fractionation; AF + ccb: Accelerated Fractionation with
Concomitant Boost; ARO: Arbeitsgemeinschaft Radioonkolgie; AUC: Area
under the curve; BfArM: Bundesinstitut für Arzneimittel und Medizinprodukte
(German Federal Institute for Drugs and Medical Devices); BfS: Bundesamt
für Strahlenschutz (German Federal Office of Radiation Protection);
CT: Computertomography; CTCAE: Common Toxicity Criteria Adverse
Events; CTV: Clinical Target Volume; DFS: Disease Free Survival; DVH: Dose
Volume Histogram; FDG: Fluorodesoxyglucose; FMISO: Fluoromisonidazol;
GTV: Gross Target Volume; Gy: Gray; HF: Hyper-fractionation; IIT: Investigator
initiated trial; IMRT: Intensity Modulated Radiotherapy; IMSE: Institut für
Medizinische Statistik und Epidemiologie; iRT: Institut für Innovative
Radiotherapie; LAHNSCC: Locally Advanced Head and Neck Squamous Cell
Cancer; LRC: Loco-regional Control; MRI: Magnetic Resonance Imaging;
MSZ: Münchner Studienzentrum; NF: Normo-fractionation; OAR: Organs at Risk;
OS: Overall Survival; PET: Positron Emission Tomography; PFS: Progression Free
Survival; PTV: Planning Target Volume; RT: Radiotherapy; RTOG: Radiation
Therapy Oncology Group; SIB: Simultaneous Integrated Boost; VMAT: Volumetric
Arc Therapy
Acknowledgements
We thank Prof Dr Fridtjof Nüsslin for initiation of the idea of this trial and his
support for application of the funding.
Funding
The ESCALOX trial is supported by the Deutsche Forschungsgemeinschaft
(DFG) project number MO 363/4-1.
Availability of data and material
Data sharing not applicable to this article as no datasets were generated or
analysed during the current study until now.
Authors’ contributions
SP, CS, JW, SC, VK, AH, HB, MS planned and co-ordinate the study. SP, SC, CS
and VK are conducting the study. Medical care is covered by SP and SC. SP
and SC are responsible for the patient recruitment. SP and SC perform planning
(delineation) SK performs planning (physics) and radiation therapy. All authors
read and approved the final manuscript.
Competing interests




Ethics approval and consent to participate
The final protocol was approved by the ethics committee of the Medical
Faculty of the Technical University of Munich (2847/10 Af).
Author details
1Department of Radiaton Oncology, Technical University of Munich, Klinikum
rechts der Isar, Ismaninger Strasse 22, D-81675 Munich, Germany. 2Münchner
Studienzentrum (MSZ Coordination Centre for Clinical Trials), Technical
University of Munich, Ismaninger Strasse 22, D-81675 Munich, Germany.
3Institute of Medical Statistics and Epidemiology (IMSE), Technical University
of Munich, Klinikum rechts der Isar, Ismaninger Strasse 22, D-81675 Munich,
Germany. 4Department of Radiation Sciences (DRS), Institut für Innovative
Radiotherapie (iRT), Helmholtz Zentrum München, Ingolstaedter Landstrasse
1, D-85764 Oberschleissheim, Germany. 5Department of Ear, Neck and Throat
(ENT), Technical University of Munich, Klinikum rechts der Isar, Ismaninger
Strasse 22, D-81675 Munich, Germany. 6Department of Nuclear Medicine,
Technical University of Munich, Klinikum rechts der Isar, Ismaninger Strasse
22, D-81675 Munich, Germany.
Pigorsch et al. Radiation Oncology  (2017) 12:45 Page 9 of 11
Received: 30 December 2016 Accepted: 6 February 2017
References
1. (Hrsg.) ZfKiRK-I. Bericht zum Krebsgeschehen in Deutschland 2016. In:
Koch-Institut ZfKiR, editor. Bericht zum Krebsgeschehen in Deutschland
2016. Berlin: Robert-Koch-Institut; 2016.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of
worldwide burden of cancer in 2008: GLOBOCAN 2008. Int Jcancer.
2010;127(12):2893–917.
3. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to
locoregional treatment for head and neck squamous-cell carcinoma: three
meta-analyses of updated individual data. MACH-NC Collaborative Group.
Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet.
2000;355(9208):949–55.
4. Pignon JP, le Maitre A, Maillard E, Bourhis J, Group M-NC. Meta-analysis of
chemotherapy in head and neck cancer (MACH-NC): an update on 93
randomised trials and 17,346 patients. Radiother Oncol. 2009;92(1):4–14.
5. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J,
Pignon JP, group M-CC. Meta-analysis of chemotherapy in head and neck
cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother
Oncol. 2011;100(1):33–40.
6. Lee NY, Le QT. New developments in radiation therapy for head and neck
cancer: intensity-modulated radiation therapy and hypoxia targeting. Semin
Oncol. 2008;35(3):236–50.
7. Seung S, Bae J, Solhjem M, Bader S, Gannett D, Hansen EK, Louie J, Underhill K,
Cha C. Intensity-modulated radiotherapy for head-and-neck cancer in the
community setting. Int J Radiat Oncol Biol Phys. 2008;72(4):1075–81.
8. Studer G, Furrer K, Davis BJ, Stoeckli SS, Zwahlen RA, Luetolf UM,
Glanzmann C. Postoperative IMRT in head and neck cancer. Radiat Oncol.
2006;1:40.
9. Studer G, Huguenin PU, Davis JB, Kunz G, Lutolf UM, Glanzmann C. IMRT
using simultaneously integrated boost (SIB) in head and neck cancer
patients. Radiat Oncol. 2006;1:7.
10. Huang K, Xia P, Chuang C, Weinberg V, Glastonbury CM, Eisele DW, Lee NY,
Yom SS, Phillips TL, Quivey JM. Intensity-modulated chemoradiation for
treatment of stage III and IV oropharyngeal carcinoma: the University of
California-San Francisco experience. Cancer. 2008;113(3):497–507.
11. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of
hyperfractionated and accelerated radiotherapy and combined
chemotherapy and radiotherapy regimens in unresected locally
advanced squamous cell carcinoma of the head and neck. BMC Cancer.
2006;6:28.
12. Negi P, Kingsley PA, Srivastava H, Sharma SK. Three Weekly Versus Weekly
Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma.
Asian Pac J Cancer Prev. 2016;17(4):1617–23.
13. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H,
Silverman C, Raben A, Galloway TJ, et al. Randomized phase III trial to test
accelerated versus standard fractionation in combination with concurrent
cisplatin for head and neck carcinomas in the Radiation Therapy Oncology
Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol Off J
Am Soc Clin Oncol. 2014;32(34):3858–66.
14. Michiels S, Le Maitre A, Buyse M, Burzykowski T, Maillard E, Bogaerts J,
Vermorken JB, Budach W, Pajak TF, Ang KK, et al. Surrogate endpoints for
overall survival in locally advanced head and neck cancer: meta-analyses of
individual patient data. Lancet Oncol. 2009;10(4):341–50.
15. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC,
Le Maitre A, Pajak TF, Poulsen MG, et al. Hyperfractionated or accelerated
radiotherapy in head and neck cancer: a meta-analysis. Lancet.
2006;368(9538):843–54.
16. Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, Garden AS,
Shenouda G, Harris J, Ang KK. Final results of local-regional control and late
toxicity of RTOG 9003: a randomized trial of altered fractionation radiation
for locally advanced head and neck cancer. Int J Radiat Oncol Biol Phys.
2014;89(1):13–20.
17. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS,
Ridge JA, Cooper JS, Ang KK. A Radiation Therapy Oncology Group
(RTOG) phase III randomized study to compare hyperfractionation and
two variants of accelerated fractionation to standard fractionation
radiotherapy for head and neck squamous cell carcinomas: first report
of RTOG 9003. Int J Radiat Oncol Biol Phys. 2000;48(1):7–16.
18. Budach V, Stuschke M, Budach W, Baumann M, Geismar D, Grabenbauer G,
Lammert I, Jahnke K, Stueben G, Herrmann T, et al. Hyperfractionated
accelerated chemoradiation with concurrent fluorouracil-mitomycin is more
effective than dose-escalated hyperfractionated accelerated radiation
therapy alone in locally advanced head and neck cancer: final results of the
radiotherapy cooperative clinical trials group of the German Cancer Society
95–06 Prospective Randomized Trial. J Clin Oncol Off J Am Soc Clin Oncol.
2005;23(6):1125–35.
19. Budach V, Stromberger C, Poettgen C, Baumann M, Budach W, Grabenbauer G,
Marnitz S, Olze H, Wernecke KD, Ghadjar P. Hyperfractionated accelerated
radiation therapy (HART) of 70.6 Gy with concurrent 5-FU/Mitomycin C is
superior to HART of 77.6 Gy alone in locally advanced head and neck cancer:
long-term results of the ARO 95–06 randomized phase III trial. Int J Radiat
Oncol Biol Phys. 2015;91(5):916–24.
20. Okunieff P, Morgan D, Niemierko A, Suit HD. Radiation dose–response of
human tumors. Int J Radiat Oncol Biol Phys. 1995;32(4):1227–37.
21. Fowler JF. Correction to Kasibhatla et al. How much radiation is the
chemotherapy worth in advanced head and neck cancer? (Int j radiat oncol
biol phys 2007;68:1491–1495). Int J Radiat Oncol Biol Phys. 2008;71(2):326–9.
22. Nutting CM, Morden JP, Harrington KJ, Urbano TG, Bhide SA, Clark C,
Miles EA, Miah AB, Newbold K, Tanay M, et al. Parotid-sparing intensity
modulated versus conventional radiotherapy in head and neck cancer
(PARSPORT): a phase 3 multicentre randomised controlled trial. Lancet
Oncol. 2011;12(2):127–36.
23. Gupta T, Agarwal J, Jain S, Phurailatpam R, Kannan S, Ghosh-Laskar S,
Murthy V, Budrukkar A, Dinshaw K, Prabhash K, et al. Three-dimensional
conformal radiotherapy (3D-CRT) versus intensity modulated radiation
therapy (IMRT) in squamous cell carcinoma of the head and neck: a
randomized controlled trial. Radiot Oncology. 2012;104(3):343–8.
24. Ghosh-Laskar S, Yathiraj PH, Dutta D, Rangarajan V, Purandare N, Gupta T,
Budrukkar A, Murthy V, Kannan S, Agarwal JP. Prospective randomized
controlled trial to compare 3-dimensional conformal radiotherapy to
intensity-modulated radiotherapy in head and neck squamous cell
carcinoma: Long-term results. Head neck. 2016;38 Suppl 1:E1481–1487.
25. Guerrero Urbano T, Clark CH, Hansen VN, Adams EJ, A’Hern R, Miles EA,
McNair H, Bidmead M, Warrington AP, Dearnaley DP, et al. A phase I study
of dose-escalated chemoradiation with accelerated intensity modulated
radiotherapy in locally advanced head and neck cancer. Radiot Oncol.
2007;85(1):36–41.
26. Schwartz M, Vuong T, Ballivy O, Parker W, Patrocinio H. Accelerated
radiotherapy with simultaneous integrated boost fractionation and
intensity-modulated radiotherapy for advanced head and neck cancer.
Otolaryngol Head Neck Surg. 2007;136(4):549–55.
27. de Arruda FF, Puri DR, Zhung J, Narayana A, Wolden S, Hunt M, Stambuk H,
Pfister D, Kraus D, Shaha A, et al. Intensity-modulated radiation therapy for
the treatment of oropharyngeal carcinoma: the Memorial Sloan-Kettering
Cancer Center experience. Int J Radiat Oncol Biol Phys. 2006;64(2):363–73.
28. Madani I, Duprez F, Boterberg T, Van de Wiele C, Bonte K, Deron P,
De Gersem W, Coghe M, De Neve W. Maximum tolerated dose in a phase I
trial on adaptive dose painting by numbers for head and neck cancer.
Radiot Oncol. 2011;101(3):351–5.
29. Duprez F, De Neve W, De Gersem W, Coghe M, Madani I. Adaptive dose
painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys.
2011;80(4):1045–55.
30. Lauve A, Morris M, Schmidt-Ullrich R, Wu Q, Mohan R, Abayomi O, Buck D,
Holdford D, Dawson K, Dinardo L, et al. Simultaneous integrated boost
intensity-modulated radiotherapy for locally advanced head-and-neck
squamous cell carcinomas: II–clinical results. Int J Radiat Oncol Biol Phys.
2004;60(2):374–87.
31. Rasmussen JH, Hakansson K, Vogelius IR, Aznar MC, Fischer BM, Friborg J,
Loft A, Kristensen CA, Bentzen SM, Specht L. Phase I trial of 18 F-
Fludeoxyglucose based radiation dose painting with concomitant cisplatin
in head and neck cancer. Radiot Oncol. 2016;120(1):76–80.
32. Dunst J, Stadler P, Becker A, Lautenschlager C, Pelz T, Hansgen G, Molls M,
Kuhnt T. Tumor volume and tumor hypoxia in head and neck cancers.
The amount of the hypoxic volume is important. Strahlenther Onkol.
2003;179(8):521–6.
33. Dunst J, Kuhnt T, Strauss HG, Krause U, Pelz T, Koelbl H, Haensgen G.
Anemia in cervical cancers: impact on survival, patterns of relapse, and
association with hypoxia and angiogenesis. Int J Radiat Oncol Biol Phys.
2003;56(3):778–87.
Pigorsch et al. Radiation Oncology  (2017) 12:45 Page 10 of 11
34. Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW. Tumor hypoxia
adversely affects the prognosis of carcinoma of the head and neck. Int J
Radiat Oncol Biol Phys. 1997;38(2):285–9.
35. Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, Becker A,
Adam M, Molls M, Dunst J, et al. Prognostic value of tumor oxygenation in
397 head and neck tumors after primary radiation therapy. An international
multi-center study. Radiot Oncol. 2005;77(1):18–24.
36. Stadler P, Feldmann HJ, Creighton C, Kau R, Molls M. Changes in tumor
oxygenation during combined treatment with split-course radiotherapy and
chemotherapy in patients with head and neck cancer. Radiot Oncol.
1998;48(2):157–64.
37. Grosu AL, Souvatzoglou M, Roper B, Dobritz M, Wiedenmann N, Jacob V,
Wester HJ, Reischl G, Machulla HJ, Schwaiger M, et al. Hypoxia imaging with
FAZA-PET and theoretical considerations with regard to dose painting for
individualization of radiotherapy in patients with head and neck cancer. Int
J Radiat Oncol Biol Phys. 2007;69(2):541–51.
38. Rischin D, Hicks RJ, Fisher R, Binns D, Corry J, Porceddu S, Peters LJ,
Trans-Tasman Radiation Oncology Group S. Prognostic significance of [18F]-
misonidazole positron emission tomography-detected tumor hypoxia in
patients with advanced head and neck cancer randomly assigned to
chemoradiation with or without tirapazamine: a substudy of Trans-Tasman
Radiation Oncology Group Study 98.02. J Clin Oncol Off J Am Soc Clin
Oncol. 2006;24(13):2098–104.
39. Rasey JS, Koh WJ, Evans ML, Peterson LM, Lewellen TK, Graham MM,
Krohn KA. Quantifying regional hypoxia in human tumors with positron
emission tomography of [18 F]fluoromisonidazole: a pretherapy study of
37 patients. Int J Radiat Oncol Biol Phys. 1996;36(2):417–28.
40. Rajendran JG, Schwartz DL, O’Sullivan J, Peterson LM, Ng P, Scharnhorst J,
Grierson JR, Krohn KA. Tumor hypoxia imaging with [F-18] fluoromisonidazole
positron emission tomography in head and neck cancer. Clin Cancer Res.
2006;12(18):5435–41.
41. Eschmann SM, Paulsen F, Bedeshem C, Machulla HJ, Hehr T, Bamberg M,
Bares R. Hypoxia-imaging with (18)F-Misonidazole and PET: changes of
kinetics during radiotherapy of head-and-neck cancer. Radiot Oncol.
2007;83(3):406–10.
42. Wang W, Georgi JC, Nehmeh SA, Narayanan M, Paulus T, Bal M,
O’Donoghue J, Zanzonico PB, Schmidtlein CR, Lee NY, et al. Evaluation
of a compartmental model for estimating tumor hypoxia via FMISO
dynamic PET imaging. Phys Med Biol. 2009;54(10):3083–99.
43. Lin Z, Mechalakos J, Nehmeh S, Schoder H, Lee N, Humm J, Ling CC. The
influence of changes in tumor hypoxia on dose-painting treatment plans
based on 18 F-FMISO positron emission tomography. Int J Radiat Oncol Biol
Phys. 2008;70(4):1219–28.
44. Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, Greco C,
Mageras G, Pham HS, Larson SM, et al. Reproducibility of intratumor
distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J
Radiat Oncol Biol Phys. 2008;70(1):235–42.
45. Lee N, Nehmeh S, Schoder H, Fury M, Chan K, Ling CC, Humm J. Prospective
trial incorporating pre-/mid-treatment [18 F]-misonidazole positron emission
tomography for head-and-neck cancer patients undergoing concurrent
chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;75(1):101–8.
46. Thorwarth D, Eschmann SM, Paulsen F, Alber M. A model of reoxygenation
dynamics of head-and-neck tumors based on serial 18 F-fluoromisonidazole
positron emission tomography investigations. Int J Radiat Oncol Biol Phys.
2007;68(2):515–21.
47. Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, Appold S,
Steinbach J, Kotzerke J, Baumann M. Exploratory prospective trial of
hypoxia-specific PET imaging during radiochemotherapy in patients with
locally advanced head-and-neck cancer. Radiot Oncol. 2012;105(1):21–8.
48. Bittner MI, Wiedenmann N, Bucher S, Hentschel M, Mix M, Weber WA,
Grosu AL. Exploratory geographical analysis of hypoxic subvolumes
using 18 F-MISO-PET imaging in patients with head and neck cancer in
the course of primary chemoradiotherapy. Radiot Oncol. 2013;108(3):511–6.
49. Eisbruch A, Kim HM, Terrell JE, Marsh LH, Dawson LA, Ship JA. Xerostomia
and its predictors following parotid-sparing irradiation of head-and-neck
cancer. Int J Radiat Oncol Biol Phys. 2001;50(3):695–704.
50. Studer G, Luetolf UM, Glanzmann C. Locoregional failure analysis in
head-and-neck cancer patients treated with IMRT. Strahlenther Onkol.
2007;183(8):417–23. discussion 424–415.
51. Vosmik M, Odrazka K, Dolezel M, Vaculikova M, Kordac P, Zouhar M, Petera J,
Jansa J, Zoul Z, Paluska P, et al. IMRT with the use of simultaneous integrated
boost in treatment of head and neck cancer: acute toxicity evaluation. Acta
Med. 2006;49(3):167–73.
52. Pacholke HD, Amdur RJ, Louis DA, Yang H, Mendenhall WM. The role of
intensity modulated radiation therapy for favorable stage tumor of the
nasal cavity or ethmoid sinus. Am J Clin Oncol. 2005;28(5):474–8.
53. Pacholke HD, Amdur RJ, Morris CG, Li JG, Dempsey JF, Hinerman RW,
Mendenhall WM. Late xerostomia after intensity-modulated radiation
therapy versus conventional radiotherapy. Am J Clin Oncol. 2005;28(4):351–8.
54. Clavel S, Nguyen DH, Fortin B, Despres P, Khaouam N, Donath D, Soulieres D,
Guertin L, Nguyen-Tan PF. Simultaneous integrated boost using intensity-
modulated radiotherapy compared with conventional radiotherapy in patients
treated with concurrent carboplatin and 5-fluorouracil for locally advanced
oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(2):582–9.
55. Adelstein DJ, Kalish LA, Adams GL, Wagner Jr H, Oken MM, Remick SC,
Mansour EG, Haselow RE. Concurrent radiation therapy and chemotherapy
for locally unresectable squamous cell head and neck cancer: an Eastern
Cooperative Oncology Group pilot study. J Clin Oncol Off J Am Soc Clin
Oncol. 1993;11(11):2136–42.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Pigorsch et al. Radiation Oncology  (2017) 12:45 Page 11 of 11
